Data Insights

LCB-14 by Iksuda Therapeutics for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

LCB-14 is under clinical development by Iksuda Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-14 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

LCB-14 by Iksuda Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

LCB-14 is under clinical development by Iksuda Therapeutics and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-14 in Gastroesophageal (GE) Junction Carcinomas

Data Insights

LCB-14 by Iksuda Therapeutics for Metastatic Breast Cancer: Likelihood of Approval

LCB-14 is under clinical development by Iksuda Therapeutics and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-14 in Metastatic Breast Cancer

Data Insights

LCB-14 by Iksuda Therapeutics for Gastric Cancer: Likelihood of Approval

LCB-14 is under clinical development by Iksuda Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-14 in Gastric Cancer

Data Insights

IKS-03 by Iksuda Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Diffuse Large B-Cell Lymphoma

Data Insights

IKS-03 by Iksuda Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Mantle Cell Lymphoma

Data Insights

IKS-03 by Iksuda Therapeutics for Follicular Lymphoma: Likelihood of Approval

IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Follicular Lymphoma

Data Insights

IKS-03 by Iksuda Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in B-Cell Non-Hodgkin Lymphoma